Metagenomi, Inc. (MGX)

Market Cap	59.63M
Revenue (ttm)	52.30M
Net Income (ttm)	-78.06M
Shares Out	37.38M
EPS (ttm)	-2.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	440,464
Open	1.630
Previous Close	1.650
Day's Range	1.561 - 1.660
52-Week Range	1.570 - 11.860
Beta	n/a
Analysts	Strong Buy
Price Target	14.40 (+802.82%)
Earnings Date	Mar 17, 2025

About MGX

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a deve...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 2024
• Employees: 236
• Stock Exchange: NASDAQ
• Ticker Symbol: MGX
• Website: https://metagenomi.co

Financial Performance

In 2024, Metagenomi's revenue was $52.30 million, an increase of 16.84% compared to the previous year's $44.76 million. Losses were -$78.06 million, 14.4% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for MGX stock is "Strong Buy." The 12-month stock price forecast is $14.4, which is an increase of 802.82% from the latest price.

Price Target

$14.4

(802.82% upside)

Analyst Consensus: Strong Buy